Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00053560
Status:
UNKNOWN
Last Update Posted:
2008-01-07
First Post:
2003-01-30
Brief Title:
To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids
Sponsor:
Genelabs Technologies
Organization:
Genelabs Technologies
Study Overview
Official Title:
A Randomized Double-Blind Multi-Center Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 Prestara in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids
Status:
UNKNOWN
Status Verified Date:
2004-11
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical trial is to study the effects of GL701 on bone mineral density in women with active systemic lupus erythematosus SLE who are also receiving treatment with glucocorticoids eg prednisone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None